{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:30:51Z","timestamp":1778509851203,"version":"3.51.4"},"reference-count":33,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Background: Higher-risk myelodysplastic neoplasms (HR-MDS) are associated with poor survival and a substantial risk of leukemic transformation. Although azacitidine is a standard treatment in this setting, comparative real-world data remain limited. We evaluated the association between azacitidine exposure and clinical outcomes in patients with HR-MDS. Methods: We performed a retrospective single-center cohort study including 72 adults with HR-MDS, defined by the Revised International Prognostic Scoring System(IPSS-R) as High or Very High risk. Patients were categorized as azacitidine-treated (Aza, n = 44) or managed with best supportive care alone (No Aza, n = 28). Overall survival (OS) was defined from diagnosis to death from any cause. Progression-free survival (PFS) was defined as the time to acute myeloid leukemia transformation or death. Leukemic transformation (LT) was analyzed using Kaplan\u2013Meier estimates and competing-risk cumulative incidence, with death without prior LT treated as a competing event. Univariable and multivariable Cox regression models were applied. Results: Azacitidine exposure was associated with longer OS compared with best supportive care, with a median OS of 13 vs.10 months and 24-month OS rates of 27% vs. 14% (p = 0.0239). PFS was also prolonged in the Aza group, with a median of 11 vs. 7 months (p = 0.0406). LT-related outcomes similarly favored azacitidine. In multivariable analyses, azacitidine remained independently associated with improved OS, PFS, and LT-related outcomes. IPSS-R Very High risk remained an adverse prognostic factor across endpoints, while a higher baseline bone marrow blast percentage independently predicted leukemic transformation. Conclusions: In this real-world HR-MDS cohort, azacitidine exposure was associated with improved survival outcomes and delayed leukemic transformation compared with best supportive care alone.<\/jats:p>","DOI":"10.3390\/medsci14020212","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T12:29:11Z","timestamp":1777033751000},"page":"212","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Clinical Outcomes of Azacitidine Versus Best Supportive Care in Higher-Risk Myelodysplastic Neoplasms: A Single-Center Cohort Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Mihai-Emilian","family":"Lapadat","sequence":"first","affiliation":[{"name":"Department of Hematology, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, Bld IC Bratianu 1-3, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana","family":"Stanca","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, Bld IC Bratianu 1-3, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina Nicoleta","family":"Triantafyllidis","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, Bld IC Bratianu 1-3, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca Mariana","family":"Ciobanu","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, Coltea Clinical Hospital, Bld IC Bratianu 1-3, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoleta Mariana","family":"Berbec","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, Bld IC Bratianu 1-3, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Negotei","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, Coltea Clinical Hospital, Bld IC Bratianu 1-3, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9009-5240","authenticated-orcid":false,"given":"Cristian Tudor","family":"Barta","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, Bld IC Bratianu 1-3, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria","family":"Bordea","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, Coltea Clinical Hospital, Bld IC Bratianu 1-3, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madalina Marilena","family":"Oprea","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, Coltea Clinical Hospital, Bld IC Bratianu 1-3, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Colita","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, Bld IC Bratianu 1-3, 030171 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"El Hussein, S., and Loghavi, S. (2022). The impact of clonal hierarchy and heterogeneity on phenotypic manifestations of myelodysplastic neoplasms. Cancers, 14.","DOI":"10.3390\/cancers14225690"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: From clonal haematopoiesis to secondary leukaemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","article-title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes","volume":"25","author":"Malcovati","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.6004\/jnccn.2025.0013","article-title":"Myelodysplastic syndromes, Version 2.2025 featured updates to the NCCN guidelines","volume":"23","author":"Greenberg","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1038\/s41375-023-02031-7","article-title":"Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts","volume":"37","author":"Platzbecker","year":"2023","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kasprzak, A., Kaivers, J., Nachtkamp, K., Haas, R., Kobbe, G., Gattermann, N., and Germing, U. (2021). Guidelines for myelodysplastic syndromes: Converting evidence into action?. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18147629"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6486","DOI":"10.1182\/blood-2023-188855","article-title":"Azacitidine treatment in MDS: A systematic literature review and meta-analysis comparing the efficacy of real world data with randomized controlled trials","volume":"142","author":"Rupp","year":"2023","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jtct.2022.11.014","article-title":"Hematopoietic cell transplantation in the management of myelodysplastic syndrome: An evidence-based review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines","volume":"29","author":"DeFilipp","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/cts.13548","article-title":"DNA methyltransferase inhibitor exposure-response: Challenges and opportunities","volume":"16","author":"Kagan","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: Mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2010-06-289280","article-title":"Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine","volume":"117","author":"Itzykson","year":"2011","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/leu.2015.115","article-title":"Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: Results from the Spanish registry","volume":"29","author":"Bernal","year":"2015","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.leukres.2014.03.004","article-title":"Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia","volume":"38","author":"Bargay","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood.V122.21.389.389","article-title":"Impact of Cytogenetics and Cytogenetic Response on Outcome in Myelodysplastic Syndromes (MDS) treated with Azacitidine (AZA). A Collaborative Study in 878 Patients","volume":"122","author":"Sebert","year":"2013","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wi\u015bniewski, K., Pruszczyk-Matusiak, K., Pu\u0142a, B., Lech-Mara\u0144da, E., and G\u00f3ra-Tybor, J. (2024). Real-World Outcome and Prognostic Factors in MDS Patients Treated with Azacitidine\u2014A Retrospective Analysis. Cancers, 16.","DOI":"10.3390\/cancers16071333"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/hon.2551","article-title":"The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group","volume":"36","author":"Papageorgiou","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/bloodadvances.2024014865","article-title":"Advancing drug development in myelodysplastic syndromes","volume":"9","author":"Mina","year":"2025","journal-title":"Blood Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jclinepi.2012.09.017","article-title":"A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions","volume":"66","author":"Latouche","year":"2013","journal-title":"J. Clin. Epidemiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3324\/haematol.2009.010611","article-title":"5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome\u2014A systematic review and meta-analysis","volume":"95","author":"Gurion","year":"2010","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.2217\/fon-2022-0334","article-title":"Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes","volume":"18","author":"Kota","year":"2022","journal-title":"Future Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ajh.23454","article-title":"Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes","volume":"88","author":"Mishra","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e43783","DOI":"10.1097\/MD.0000000000043783","article-title":"Prognosis of the transformation of myelodysplastic syndromes to acute myeloid leukemia: A retrospective study","volume":"104","author":"Wang","year":"2025","journal-title":"Medicine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.leukres.2015.03.006","article-title":"Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up","volume":"39","author":"Cabrero","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zavras, P.D., Sinanidis, I., Tsakiroglou, P., and Karantanos, T. (2023). Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24055018"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/ajh.23303","article-title":"Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes","volume":"87","author":"Komrokji","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.annonc.2020.11.002","article-title":"Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Fenaux","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.2012.074831","article-title":"A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial","volume":"98","author":"Gore","year":"2013","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pds.1357","article-title":"Immortal time bias in observational studies of drug effects","volume":"16","author":"Suissa","year":"2007","journal-title":"Pharmacoepidemiol. Drug Saf."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/2\/212\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:41:42Z","timestamp":1778506902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/2\/212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["medsci14020212"],"URL":"https:\/\/doi.org\/10.3390\/medsci14020212","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]}}}